Cargando…
P893: CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (KRD) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS: ITALIAN, MULTICENTER, RETROSPECTIVE EXPERIENCE OUTSIDE OF CLINICAL TRIALS
Autores principales: | Martino, E. A., Conticello, C., Zamagni, E., Pavone, V., Palmieri, S., Musso, M., Tacchetti, P., Mele, A., Catlano, L., Vigna, E., Bruzzese, A., Mendicino, F., Botta, C., Vincelli, D., Farina, G., Barone, M., Cangialosi, C., Mancuso, K., Rizziello, I., Rocchi, S., Falcone, A. P., Mele, G., Reddiconto, G., Garibaldi, B., Iaccino, E., Tripepi, G., Di Raimondo, F., Musto, P., Neri, A., Cavo, M., Morabito, F., Gentile, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431267/ http://dx.doi.org/10.1097/01.HS9.0000846444.09478.3f |
Ejemplares similares
-
PB2016: COMPARISON BETWEEN DRD VS KRD AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS IN FIRST RELAPSE: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP)
por: Mele, A., et al.
Publicado: (2022) -
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
por: Morabito, Fortunato, et al.
Publicado: (2022) -
PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS
por: Bruzzese, A., et al.
Publicado: (2022) -
Front-line treatment of multiple myeloma
por: Cavo, Michele, et al.
Publicado: (2019) -
The Relative Dangers of Anæsthesia by Chloroform and Ether—Statistics of 209,893 Cases
por: Andrews, E.
Publicado: (1870)